Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation
- 13 February 2007
- journal article
- research article
- Published by Elsevier in Heart Rhythm
- Vol. 4 (6) , 743-749
- https://doi.org/10.1016/j.hrthm.2007.02.006
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (HL075266, HL65962)
This publication has 60 references indexed in Scilit:
- Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillationHeart Rhythm, 2005
- Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failureJournal of the American College of Cardiology, 2004
- ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial FibrillationCirculation, 2004
- Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertensionThe American Journal of Cardiology, 1996
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.Journal of Clinical Investigation, 1990
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- The Natural History of Lone Atrial FibrillationNew England Journal of Medicine, 1987
- Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart studyThe American Journal of Cardiology, 1987
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsPublished by Elsevier ,1986
- Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.Circulation, 1977